Penumbra Reports 90-Day Results of STORM-PE Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy PEN?
Source: PRnewswire
- Clinical Trial Results: Penumbra's STORM-PE trial revealed that patients with acute intermediate-high risk pulmonary embolism treated with computer-assisted vacuum thrombectomy (CAVT™) plus anticoagulation showed significant functional improvements at 90 days, including increased walking distance and a higher proportion achieving NYHA Class I, indicating the substantial clinical potential of CAVT.
- Safety Confirmation: Over the 90-day observation period, safety rates were comparable between the CAVT and anticoagulation groups, with no device-related mortality and no significant differences in PE-related mortality after 7 days, further validating the safety profile of CAVT and supporting its clinical application.
- Evolving Treatment Strategies: The results from the STORM-PE trial underscore the importance of CAVT in treating intermediate-high risk pulmonary embolism, potentially leading to a shift in future clinical guidelines towards broader adoption of endovascular treatment options, thereby improving patient recovery and quality of life.
- Future Research Directions: The upcoming STRIKE-PE study, set to present on April 15, will provide long-term quality-of-life and functional outcome data for CAVT in male and female pulmonary embolism patients, further validating the clinical efficacy of CAVT and advancing the treatment landscape for pulmonary embolism.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PEN
Wall Street analysts forecast PEN stock price to rise
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 332.170
Low
266.00
Averages
344.64
High
388.00
Current: 332.170
Low
266.00
Averages
344.64
High
388.00
About PEN
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Penumbra Reports 90-Day Results of STORM-PE Trial
- Clinical Trial Results: Penumbra's STORM-PE trial revealed that patients with acute intermediate-high risk pulmonary embolism treated with computer-assisted vacuum thrombectomy (CAVT™) plus anticoagulation showed significant functional improvements at 90 days, including increased walking distance and a higher proportion achieving NYHA Class I, indicating the substantial clinical potential of CAVT.
- Safety Confirmation: Over the 90-day observation period, safety rates were comparable between the CAVT and anticoagulation groups, with no device-related mortality and no significant differences in PE-related mortality after 7 days, further validating the safety profile of CAVT and supporting its clinical application.
- Evolving Treatment Strategies: The results from the STORM-PE trial underscore the importance of CAVT in treating intermediate-high risk pulmonary embolism, potentially leading to a shift in future clinical guidelines towards broader adoption of endovascular treatment options, thereby improving patient recovery and quality of life.
- Future Research Directions: The upcoming STRIKE-PE study, set to present on April 15, will provide long-term quality-of-life and functional outcome data for CAVT in male and female pulmonary embolism patients, further validating the clinical efficacy of CAVT and advancing the treatment landscape for pulmonary embolism.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Odyssey Marine Exploration, Inc. (NASDAQ:OMEX) for potential breaches of fiduciary duties related to its merger with American Ocean Minerals Corporation, aiming to protect investor rights.
- Potential Financial Benefits: Penumbra, Inc. (NYSE:PEN) is being sold for $374 in cash or 3.8721 shares of Boston Scientific common stock, with Halper Sadeh LLC potentially seeking increased compensation for shareholders to ensure fair treatment.
- Shareholder Rights Protection: Sun Country Airlines Holdings, Inc. (NASDAQ:SNCY) is selling for 0.1557 shares of Allegiant common stock and $4.10 in cash, and Halper Sadeh LLC encourages shareholders to understand their rights and options to ensure transaction transparency.
- Commitment to Legal Support: Clearwater Analytics Holdings, Inc. (NYSE:CWAN) is being sold for $24.55 per share in cash, and Halper Sadeh LLC is committed to providing legal support to global investors, helping victims recover losses and pushing for corporate reforms.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Enhabit, Inc. (NYSE:EHAB) for its sale to Kinderhook Industries, LLC at $13.80 per share in cash, potentially violating fiduciary duties and impacting shareholder rights.
- Potential Violations: The firm is also scrutinizing Silicon Laboratories Inc. (NASDAQ:SLAB) for its sale to Texas Instruments at $231.00 per share in cash, which may limit superior competing offers and harm ordinary shareholders' interests.
- Shareholder Rights Protection: The investigation extends to Penumbra, Inc. (NYSE:PEN), which is being sold for $374.00 in cash or 3.8721 shares of Boston Scientific common stock, with Halper Sadeh LLC potentially seeking increased compensation and additional disclosures for shareholders.
- Legal Service Commitment: SkyWater Technology, Inc. (NASDAQ:SKYT) is under review for its sale at $15.00 in cash and $20.00 in IonQ common stock, with Halper Sadeh LLC promising no upfront legal fees to protect shareholder rights.
See More
Emerging Consolidation Wave in U.S. Markets
- Resurgence of M&A Activity: Over the six months ending March 2026, U.S. merger activity remained robust, with monthly deal counts consistently between 1,000 and 1,300, indicating strong market demand for consolidation despite volatility and macro uncertainty.
- Sector Concentration Trend: Frequent mergers in consumer health, semiconductors, medical devices, and media entertainment suggest that companies in these sectors are consolidating to enhance scale and competitiveness in response to rising costs and technological pressures.
- Clear Strategic Motivations: In consumer products, companies merge brand portfolios to strengthen negotiating power with retailers; semiconductor firms seek scale due to rising R&D costs; and medical technology companies acquire innovative platforms to accelerate product development.
- Emerging Investment Opportunities: As the consolidation wave accelerates, investors should focus on identifying companies that may become acquisition targets, as recognizing integration opportunities within industries could yield significant returns.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Potential Violation Investigation: Halper Sadeh LLC is investigating Penumbra, Inc. (NYSE: PEN) regarding its sale to Boston Scientific Corporation, which involves either $374 in cash or 3.8721 shares of Boston Scientific common stock, potentially indicating breaches of fiduciary duties to shareholders.
- Merger Transaction Impact: Upon completion of the merger between Brink’s Company (NYSE: BCO) and NCR Atleos Corporation, Brink’s shareholders will own approximately 78% of the combined entity, which could significantly affect shareholder rights and future earnings.
- Cash Acquisition Proposal: AES Corporation (NYSE: AES) is being acquired by a consortium led by Global Infrastructure Partners and EQT Infrastructure VI fund for $15.00 per share in cash, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures for shareholders.
- Legal Rights Consultation: Halper Sadeh LLC encourages shareholders to consult about their rights and options at no cost, emphasizing their capability in providing legal support against securities fraud and corporate misconduct.
See More
Monteverde Law Firm Investigates Multiple Mergers
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Thermon Group Holdings and CECO Environmental, where Thermon shareholders may choose to receive $10 in cash and 0.6840 shares of CECO stock per share, or $63.89 in cash, or 0.8110 shares of CECO stock, which will directly impact shareholder financial returns.
- Penumbra Transaction Details: In the deal involving Penumbra, Inc. and Boston Scientific Corporation, Penumbra shareholders are expected to receive either 3.8721 shares of Boston Scientific common stock or $374 in cash per share, providing significant cash flow and potential stock appreciation for shareholders.
- Brink's Merger Proposal: In the merger between Brink’s Company and NCR Atleos Corporation, NCR Atleos shareholders are expected to receive $30 in cash and 0.1574 shares of Brink’s common stock per share, offering NCR shareholders stable cash returns and future equity appreciation opportunities.
- Allegiant Merger Outlook: The merger between Allegiant Travel Company and Sun Country Airlines is expected to result in Allegiant shareholders owning approximately 67% of the combined company, significantly enhancing Allegiant's competitiveness and market share in the airline industry.
See More
Penumbra Reports 90-Day Results of STORM-PE Trial
- Clinical Trial Results: Penumbra's STORM-PE trial revealed that patients with acute intermediate-high risk pulmonary embolism treated with computer-assisted vacuum thrombectomy (CAVT™) plus anticoagulation showed significant functional improvements at 90 days, including increased walking distance and a higher proportion achieving NYHA Class I, indicating the substantial clinical potential of CAVT.
- Safety Confirmation: Over the 90-day observation period, safety rates were comparable between the CAVT and anticoagulation groups, with no device-related mortality and no significant differences in PE-related mortality after 7 days, further validating the safety profile of CAVT and supporting its clinical application.
- Evolving Treatment Strategies: The results from the STORM-PE trial underscore the importance of CAVT in treating intermediate-high risk pulmonary embolism, potentially leading to a shift in future clinical guidelines towards broader adoption of endovascular treatment options, thereby improving patient recovery and quality of life.
- Future Research Directions: The upcoming STRIKE-PE study, set to present on April 15, will provide long-term quality-of-life and functional outcome data for CAVT in male and female pulmonary embolism patients, further validating the clinical efficacy of CAVT and advancing the treatment landscape for pulmonary embolism.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Odyssey Marine Exploration, Inc. (NASDAQ:OMEX) for potential breaches of fiduciary duties related to its merger with American Ocean Minerals Corporation, aiming to protect investor rights.
- Potential Financial Benefits: Penumbra, Inc. (NYSE:PEN) is being sold for $374 in cash or 3.8721 shares of Boston Scientific common stock, with Halper Sadeh LLC potentially seeking increased compensation for shareholders to ensure fair treatment.
- Shareholder Rights Protection: Sun Country Airlines Holdings, Inc. (NASDAQ:SNCY) is selling for 0.1557 shares of Allegiant common stock and $4.10 in cash, and Halper Sadeh LLC encourages shareholders to understand their rights and options to ensure transaction transparency.
- Commitment to Legal Support: Clearwater Analytics Holdings, Inc. (NYSE:CWAN) is being sold for $24.55 per share in cash, and Halper Sadeh LLC is committed to providing legal support to global investors, helping victims recover losses and pushing for corporate reforms.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Enhabit, Inc. (NYSE:EHAB) for its sale to Kinderhook Industries, LLC at $13.80 per share in cash, potentially violating fiduciary duties and impacting shareholder rights.
- Potential Violations: The firm is also scrutinizing Silicon Laboratories Inc. (NASDAQ:SLAB) for its sale to Texas Instruments at $231.00 per share in cash, which may limit superior competing offers and harm ordinary shareholders' interests.
- Shareholder Rights Protection: The investigation extends to Penumbra, Inc. (NYSE:PEN), which is being sold for $374.00 in cash or 3.8721 shares of Boston Scientific common stock, with Halper Sadeh LLC potentially seeking increased compensation and additional disclosures for shareholders.
- Legal Service Commitment: SkyWater Technology, Inc. (NASDAQ:SKYT) is under review for its sale at $15.00 in cash and $20.00 in IonQ common stock, with Halper Sadeh LLC promising no upfront legal fees to protect shareholder rights.
See More
Emerging Consolidation Wave in U.S. Markets
- Resurgence of M&A Activity: Over the six months ending March 2026, U.S. merger activity remained robust, with monthly deal counts consistently between 1,000 and 1,300, indicating strong market demand for consolidation despite volatility and macro uncertainty.
- Sector Concentration Trend: Frequent mergers in consumer health, semiconductors, medical devices, and media entertainment suggest that companies in these sectors are consolidating to enhance scale and competitiveness in response to rising costs and technological pressures.
- Clear Strategic Motivations: In consumer products, companies merge brand portfolios to strengthen negotiating power with retailers; semiconductor firms seek scale due to rising R&D costs; and medical technology companies acquire innovative platforms to accelerate product development.
- Emerging Investment Opportunities: As the consolidation wave accelerates, investors should focus on identifying companies that may become acquisition targets, as recognizing integration opportunities within industries could yield significant returns.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Potential Violation Investigation: Halper Sadeh LLC is investigating Penumbra, Inc. (NYSE: PEN) regarding its sale to Boston Scientific Corporation, which involves either $374 in cash or 3.8721 shares of Boston Scientific common stock, potentially indicating breaches of fiduciary duties to shareholders.
- Merger Transaction Impact: Upon completion of the merger between Brink’s Company (NYSE: BCO) and NCR Atleos Corporation, Brink’s shareholders will own approximately 78% of the combined entity, which could significantly affect shareholder rights and future earnings.
- Cash Acquisition Proposal: AES Corporation (NYSE: AES) is being acquired by a consortium led by Global Infrastructure Partners and EQT Infrastructure VI fund for $15.00 per share in cash, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures for shareholders.
- Legal Rights Consultation: Halper Sadeh LLC encourages shareholders to consult about their rights and options at no cost, emphasizing their capability in providing legal support against securities fraud and corporate misconduct.
See More
Monteverde Law Firm Investigates Multiple Mergers
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Thermon Group Holdings and CECO Environmental, where Thermon shareholders may choose to receive $10 in cash and 0.6840 shares of CECO stock per share, or $63.89 in cash, or 0.8110 shares of CECO stock, which will directly impact shareholder financial returns.
- Penumbra Transaction Details: In the deal involving Penumbra, Inc. and Boston Scientific Corporation, Penumbra shareholders are expected to receive either 3.8721 shares of Boston Scientific common stock or $374 in cash per share, providing significant cash flow and potential stock appreciation for shareholders.
- Brink's Merger Proposal: In the merger between Brink’s Company and NCR Atleos Corporation, NCR Atleos shareholders are expected to receive $30 in cash and 0.1574 shares of Brink’s common stock per share, offering NCR shareholders stable cash returns and future equity appreciation opportunities.
- Allegiant Merger Outlook: The merger between Allegiant Travel Company and Sun Country Airlines is expected to result in Allegiant shareholders owning approximately 67% of the combined company, significantly enhancing Allegiant's competitiveness and market share in the airline industry.
See More
